Therapy Areas: Central Nervous System
Insilico Medicine and Tenacia expand AI-driven R&D collaboration
27 March 2026 - Insilico Medicine (HK:3696), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Tenacia Biotechnology (Hong Kong) Co Limited, a China-based, com...
TheraCryf advances lead addiction programme to final preclinical stage
23 March 2026 - TheraCryf plc (AIM: TCF), a UK-based biotech company that develops new medicines for addiction and other neuropsychiatric disorders, announced on Monday that it has completed preclinic...
Collegium to acquire AZSTARYS from Corium Therapeutics
20 March 2026 - Collegium Pharmaceutical Inc (Nasdaq:COLL) and Corium Therapeutics Holdings LLC announced on Thursday a definitive agreement for Collegium to acquire AZSTARYS for USD650m in cash with ...
Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease
18 March 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designati...
GenomOncology partners with WeTrials to support CNS cancer clinical trials
11 March 2026 - Precision medicine software company GenomOncology announced on Tuesday that it has partnered with WeTrials, an AI-powered patient engagement and trial enablement platform, to help cent...
Genentech's fenebrutinib meets primary endpoint in pivotal Phase III study for multiple sclerosis
2 March 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Monday that its Phase III FENhance 1 study in relapsing multiple sclerosis (RMS)...